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Summary
Epstein-Barr virus (EBV) is associated with several malignancies, including
post-transplant lymphoproliferative disorder (PTLD). Conventional treat-
ments for PTLD are often successful, but risk organ rejection and cause sig-
nificant side effects. EBV-specific cytotoxic T lymphocytes (CTLs)
generated in vitro from peripheral blood lymphocytes provide an alternative
treatment modality with few side effects, but autologous CTLs are difficult
to use in clinical practice. Here we report the establishment and operation
of a bank of EBV-specific CTLs derived from 25 blood donors with human
leucocyte antigen (HLA) types found at high frequency in European popu-
lations. Since licensure, there have been enquiries about 37 patients, who
shared a median of three class I and two class II HLA types with these
donors. Cells have been infused into ten patients with lymphoproliferative
disease, eight of whom achieved complete remission. Neither patient with
refractory disease was matched for HLA class II. Both cases of EBV-associ-
ated non-haematopoietic sarcoma receiving cells failed to achieve complete
remission. Thirteen patients died before any cells could be issued, empha-
sizing that the bank should be contacted before patients become pre-termi-
nal. Thus, this third party donor-derived EBV-specific CTL cell bank can
supply most patients with appropriately matched cells and most recipients
have good outcomes.
Keywords: cell therapy, Epstein-Barr virus, cytotoxicity, lymphoproliferative
disease.
Epstein-Barr virus (EBV) infects most humans, sometimes
causing infectious mononucleosis (Visser et al, 2014), but
always establishing a life-long latent infection in B lympho-
cytes. This state is usually considered to be asymptomatic,
but has been associated with both predisposition to autoim-
mune diseases (Almohmeed et al, 2013; Hanlon et al, 2014)
and several malignancies (Chen et al, 2012; Roschewski &
Wilson, 2012), including post-transplant lymphoproliferative
disorder (PTLD). Initial treatment for PTLD comprises
reduction of immunosuppression and rituximab (Messahel
et al, 2006), with or without chemotherapy (Heslop, 2009).
However, the condition continues to have a high mortality
from both refractory disease and complications of treatment.
In addition, as it often occurs in the context of otherwise
successful transplants, it may cause donated organs to be
wasted.
Data from infected but healthy individuals show the
importance of cytotoxic T cell (CTL) responses in the con-
trol of latent EBV infection (Hislop et al, 2007). The risk of
PTLD correlates inversely with anti-EBV T cell activity in
patients, particularly in children who have not previously
encountered the virus (Abu-Elmagd et al, 2009). Cellular
therapy was first shown to be effective against PTLD in the
form of unmanipulated donor lymphocyte infusions after
bone marrow transplantation (Papadopoulos et al, 1994).
Autologous or donor-derived CTLs directed specifically
against EBV were subsequently developed and are a non-
toxic but still effective form of treatment (Heslop et al, 2010;
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Bollard et al, 2012). However, several factors have worked
against their widespread adoption as a therapeutic modality.
In particular, the low incidence of PTLD (1–5%) means that
the generation of prophylactic autologous CTLs in advance
for patients is not usually cost-effective, although the refine-
ment of risk factors may make prediction worthwhile (Uhlin
et al, 2014). The lengthy period, typically 2–3 months, neces-
sary for CTL culture makes their generation post-diagnosis
difficult in a clinically useful timeframe. Finally, the per-
ceived efficacy of chemotherapeutic regimens containing rit-
uximab has rendered autologous anti-EBV CTLs to be
considered unviable as a clinical product. Nevertheless, about
one-third of patients with a diagnosis of PTLD continue to
die either from PTLD itself or complications of treatment
(Burns et al, 2013; Caillard et al, 2013; Styczynski et al, 2013;
Uhlin et al, 2014).
Thus, several strategies are being employed to enhance the
effectiveness of CTLs (Bollard et al, 2014). In haematopoietic
stem cell transplantation (HSCT), donor lymphocytes
responding to EBV can be collected by apheresis, selected by
cytokine secretion and infused within days of diagnosis into
patients (Moosmann et al, 2010; Uhlin et al, 2012; Gerde-
mann et al, 2013). An alternative approach that we, and oth-
ers, have used is to pre-prepare a bank of EBV-specific CTLs
from third party donors. This approach was described in
2001 (Haque et al, 2001) and developed over subsequent
years, (Haque et al, 2002; Wilkie et al, 2004), with a trial
reporting overall responses of 64% at 5 weeks and 52% (14
complete and three partial in 33 patients) at 6 months
(Haque et al, 2007, 2010). Other groups have reported the
use of third party donors with similar outcomes in PTLD
and we have summarized these data in Table I (Sun et al,
2002; Barker et al, 2010; Doubrovina et al, 2012; Leen et al,
2013). However, cell banks developed in the context of
research laboratories had to be abandoned for clinical use in
Europe after 2005, as they were not made in accordance with
Good Manufacturing Practice (GMP) and relevant European
Commission (EC) legislation, most recently Regulation No
1394/2007 ‘designed to ensure the free movement of
advanced therapy products within Europe, to facilitate access
to the EU market and to foster the competitiveness of Euro-
pean companies in the field, while guaranteeing the highest
level of health protection for patients’. In response, the Well-
come Trust and Scottish National Blood Transfusion Service
(SNBTS) funded the set up of a GMP-compliant cell bank,
which was licenced by the Medicines and Healthcare prod-
ucts Regulatory Agency (MHRA) to start supplying CTLs in
February 2012. Here we report the operation and outcomes
of the bank after 2 years of operation.
Establishment of cell bank
Peripheral blood mononuclear cell (PBMC) donations were
kindly provided by donors located in New Zealand in order
to minimize the risk of Creutzfeldt–Jacob disease transmis-
sion. The New Zealand Blood Service provided access to a
human leucocyte antigen (HLA)-typed, pre-screened aphere-
sis donor panel. Each donor gave informed consent and was
required to test positive for antibodies against EBV viral cap-
sid antigen, preferably be blood group O and test negative
for antibodies to Hepatitis B virus (HBV), Hepatitis C virus
(HCV), human immunodeficiency virus (HIV), human T-
lymphotropic virus type I (HTLV1) and syphilis. In addition,
donors were selected to maximize the probability of HLA
class I and II matches and minimize the number of mis-
matches. This was performed by taking the HLA types of 304
patients from the East of Scotland renal transplant waiting
list and performing simulations using 200 donors from the
Auckland, New Zealand platelet apheresis donor panel. Anti-
gens shared between putative donor-recipient pairs were
scored as ‘2’ for two antigens shared at any one locus, ‘1’ for
one antigen shared and ‘0’ if no antigens were shared. At a
minimum low-resolution level mismatch (HLA-A, -B, DRB1
‘111’ or better), it was found that 15 well-selected donors
could cover 57% of the patient population. This rose to 85%
with 25 donors, but further increases in the size of the puta-
tive donor panel did not significantly increase the number of
matches. The panel size chosen was therefore 25 and donors
are listed in Table II. Due to the mismatch minimization
procedure used, HLA homozygotes are over-represented.
Approximately 25–50 9 109 mononuclear cells (MNCs)
were collected from each of 25 donors into 10 bags by apher-
esis, cryopreserved in 10% dimethyl sulfoxide (DMSO), then
shipped to the UK in vapour phase liquid nitrogen by an
accredited shipper with temperature logging throughout. On
receipt, cells were transferred to vapour storage. Culture con-
ditions have been described previously (Wilkie et al, 2004),
but briefly: an aliquot of MNCs was infected with purified
EBV, manufactured by a US Food and Drug Administration
(FDA) registered facility at the Baylor College of Medicine
(Houston, TX, USA), and lymphoblastoid cell lines (LCLs)
established over 4–8 weeks. LCLs express the type III latency
pattern proteins associated with PTLD and are also efficient
antigen-presenting cells, expressing both HLA class I and II
as well as several co-stimulatory ligands. LCLs were irradiated
and used for antigen stimulation on a revived aliquot of
MNCs at an initial ratio of 40:1 MNC:LCL. Subsequent
Table I. Previous experience of third party derived CTLs in the
treatment of PTLD.
n
Partial
response
Complete
response
Overall
response
rate (%)
Sun et al (2002) 2 0 2 100
Haque et al (2007, 2010) 33 3 14 52
Doubrovina et al (2012) 19 0 13 68
Leen et al (2013) 9 4 2 67
Totals 63 7 31 (47%) 60
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weekly stimulations used a 4:1 CTL:LCL ratio with 20 iu/ml
interleukin- 2 (IL2) added thrice weekly from 14 d. EBV-spe-
cific CTLs were expanded over approximately 2 months, then
cryopreserved in 10% DMSO frozen in Origen CryoStore
bags of 50 9 106 or 150 9 106 cells using a controlled rate
freezer, before placing in nitrogen vapour-phase storage at
<150°C. Final product samples passed bacterial, myco-
plasma, viral and endotoxin testing as negative or not
detected. Bacterial testing was by SNBTS standard procedure
using the BacT/Alert 3D system (BioMerieux, Basingstoke,
UK). Mycoplasma 28-d cultural testing was according to test
requirements of PhEur-2008, by Mycoplasma Experience
(Reigate, UK). Viral nucleic acid amplification testing was of
HCV, HIV and HBV by SNBTS. Endotoxin levels were tested
using Biowhittaker LAL methodology (Cambrex Bio Science
Walkersville, Inc., Walkersville, MD, USA) by SNBTS. Sam-
ples were immunophenotyped for CD3, CD4, CD8, CD19
and CD56 and were required to be <2% CD19+. Cytotoxic
function and anti-viral specificity were tested using a flow cy-
tometric-based assay based on previously reported methods
(Derby et al, 2001). CTLs were incubated at 20:1, 10:1, 5:1
and 25:1 effector:target ratios, in 96 round-welled plates, in
RPMI medium supplemented with 20% fetal bovine serum
(FBS), for 4 h with PKH67-stained targets. Target cells, at
104/well, comprised autologous LCLs, EBV-uninfected phyto-
haemoagglutinin (PHA)-stimulated lymphoblasts, HLA-mis-
matched LCLs and K562 (a natural killer cell target). After a
further 20-min incubation with 7-aminoactinomycin D
(7AAD) to stain non-viable cells, samples were run through
a flow cytometer. The percentage of double positive stained
cells in test wells minus the respective target-only wells, gave
an indication of killing after incubation. CTLs were required
to demonstrate functionality, by having autologous LCL kill-
ing >10%, and specificity, by <10% or lower killing of the
other target cells. The documentation in each batch record
was reviewed by the quality department prior to authoriza-
tion for release.
The MHRA certified compliance with GMP and awarded
a ‘Specials’ Licence, allowing the release of an Advanced
Therapy Medicinal Product (ATMP) in October 2011. A final
quality sign-off was performed in February 2012. At licensure
only three CTL lines were available for use; this number
gradually increased over the next 18 months to the full com-
plement of 25. After an enquiry is made to the bank, the
referring clinicians are requested to complete an Initial
Patient Enquiry form, which includes information on HLA
types and any anti-HLA antibodies. If a suitable HLA match
is found, a blood sample is requested to verify the HLA type,
Table II. HLA types of unrelated donors.
CTL ID
HLA Class I HLA Class II
IssuesA* B* C* DRB1* DQB1*
NZ020 23:01 68:01 15:01 18:01 03:03 07:01 11:01 15:01 03:01 06:02
NZ026 29:02 29:02 44:03 51:07 14:02 16:01 07:01 11:01 02:02 03:01
NZ111 02:01 02:01 13:02 27:05 02:02 06:02 01:01 15:01 05:01 06:02
NZ153 01:01 02:01 08:01 15:01 03:04 07:01 03:01 13:01 02:01 06:03
NZ177 02:01 02:01 51:01 57:01 02:02 06:02 13:01 15:01 06:02 06:03
NZ200 01:01 31:01 08:01 40:01 03:04 07:01 03:01 04:04 02:01 03:02
NZ209 01:01 02:01 08:01 44:02 05:01 07:01 03:01 11:03 02:01 03:01 2
NZ294 02:01 03:01 14:02 44:03 08:02 16:01 07:01 13:02 02:02 06:09
NZ298 01:01 29:02 07:02 44:03 07:02 16:01 07:01 07:01 02:01 02:01
NZ327 02:01 02:01 44:02 44:02 05:01 05:01 11:01 12:01 03:01 03:01
NZ332 02:01 24:02 40:01 44:02 03:04 07:04 11:01 13:02 03:01 06:04
NZ417 32:01 68:01 44:02 44:02 05:01 07:04 13:01 14:01 05:03 06:03
NZ449 02:01 02:01 07:02 44:02 05:01 07:02 04:01 15:01 03:02 06:02
NZ578 01:01 03:01 08:01 57:01 06:02 07:01 03:01 07:01 02:01 03:03
NZ610 03:01 68:02 14:02 51:01 08:02 15:02 01:01 13:03 03:01 05:01
NZ612 01:01 02:01 18:01 35:02 04:01 07:01 11:04 11:04 03:01 06:03
NZ666 01:01 24:02 08:01 15:18 03:03 07:01 03:01 11:06 02:01 03:01
NZ675 26:01 26:01 49:01 51:01 07:01 16:02 01:01 13:02 05:04 06:04
NZ771 11:01 26:01 27:05 35:01 02:02 04:01 04:01 11:01 03:01 03:01
NZ806 01:01 01:01 08:01 08:01 07:01 07:01 03:01 03:01 02:01 02:01 2
NZ823 02:01 32:01 15:01 15:01 03:03 03:03 03:01 15:01 02:01 06:02
NZ873 01:01 03:01 07:02 08:01 07:01 07:02 03:01 15:01 02:01 06:02 5
NZ898 02:01 32:01 14:01 44:02 05:01 08:02 04:01 07:01 02:02 03:02
NZ932 02:01 26:08 40:02 51:01 02:02 15:02 01:01 11:01 03:01 05:01 1
NZ988 02:01 03:01 44:02 44:02 07:04 08:02 04:01 04:01 03:01 03:02 1
HLA, human leucocyte antigen; CTL ID, cytotoxic T lymphocytes identification code.
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detect any anti-HLA antibodies and also check that no non-
specific cell killing is seen. A sample of proposed CTLs is
tested in a repeat cytotoxicity assay against autologous LCLs
to confirm cytotoxic function (positive control) and patient
phytohaemagglutinin (PHA)–stimulated blasts to check that
they are not killed. Cells are then shipped to a Human Tissue
Authority (HTA) licenced receiving centre, along with infor-
mation sheets and infusion instructions. CTLs are infused at
doses of 12 9 106/kg body weight as a course of four infu-
sions given at weekly intervals. All forms are downloadable
from our website (http://www.scotblood.co.uk/about-us/clini-
cal-services/cytotoxic-t-cell-therapy.aspx). Correspondence is
generally carried out from nss.ctlbank@nhs.net. A non-profit
making, cost recovery charge of £12 500 is charged for the
supply of cells.
Operation of the cell bank
Enquiries before licensure. In the year before the certification
of compliance with GMP, eleven enquiries about CTLs were
received, which had to be declined as we had not yet
received a Manufacturer’s licence. Nine of the eleven patients
had confirmed EBV+ PTLD and six of these patients are
believed to have died. Of the three who survived, one patient
travelled to America for CTL therapy and two responded to
conventional therapies. The two other enquiries comprised a
presumptive diagnosis of chronic active EBV infection and a
girl with a congenital immunodeficiency with previous EBV-
associated lymphoproliferative disorder being prepared for an
unrelated donor peripheral progenitor cell transplant. The
former diagnosis was changed to angioimmunoblastic T cell
lymphoma and secondary activation of EBV, with a fatal out-
come. We were asked to grow CTLs from a prospective
donor for the second, but the donation centre was unable to
supply PBMC. The transplant went ahead with prophylactic
rituximab used against the risk of PTLD, but the patient died
of thrombotic thrombocytopenic purpura and adenoviral
infection. Thus, overall, eight of the eleven enquiries pre-
licensure had a fatal outcome.
Enquiries resulting in issue of CTLs. In the 21 months since
licensure, and 3 months post manufacturing certification,
but pre-licensure, 37 enquiries were received. The frequency
of enquiries increased slightly during this time (Fig 1).
Twelve of these enquiries resulted in the issue of CTLs
(Table III). Nine of the twelve (Patients 1, 3, 4, 7, 8, 9, 10,
11, 12) were cases of PTLD. Of these, one was CD20- and
rituximab-resistant (Patient 1), one had concomitant graft-
versus-host disease (GVHD) precluding reduction of immu-
nosuppression (Patient 3), one was unfit for chemotherapy
because of recent necrotizing fasciitis and multi-organ failure
(Patient 4) and six cases had the CTLs used to consolidate
reduction of immunosuppression and chemotherapy. Four
patients had central nervous system (CNS) disease, where rit-
uximab penetration is known to be poor. Of these nine,
seven went into complete remission, while two (Patients 3,
9) had progressive disease and died within weeks of the infu-
sions. Neither of these two had an HLA class II match (see
below), although both had three HLA class I matches. Both
also had relatively rapidly progressive disease at the time of
infusions. In a further two cases (Patients 2, 5), the CTLs
were planned to be used as a bridge to allogeneic HSCT for
0
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2
Enquiries
CTLs issued
Died
Recovered
without 
infusion
Recovered 
after CTL
infusion
Months before/after licensure
2 4 6 8 10 12–2–4–6–8–10 14 16 18 200
*1
*2
*1
22 24
*3 *3
Fig 1. Timeline of bank summarizing enquiries
and outcomes. Months before licensure are
shown as negative numbers on the horizontal
axis, and months after as positive numbers.
Cases are indicated by stacked bars and are
ordered by time at which initial contact was
made with the bank. *1 indicates a directed
donation from the father of the patient; the
cytotoxic T lymphocytes (CTLs) were infused
after licensure. *2 indicates that the issued
CTLs have not yet been infused. *3 indicates
that the patients had EBV-associated non-hae-
matopoietic sarcoma, the other recipients had
post-transplant proliferative disorder.
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EBV+ lymphoproliferation associated with congenital immu-
nosuppression, although only one of these has been infused
at the time of writing.
Cytotoxic T lymphocytes were also infused into two cases
of EBV-associated non-haematopoietic sarcomas. One
(Patient 6) had chemotherapy-resistant EBV-associated leio-
myosarcoma post-cardiac transplant and the CTLs were
derived from the father of the patient. In the computerized
tomography scan taken 6 weeks after the last infusion, sev-
eral of the lesions had decreased in size and there were no
new lesions, which was felt to represent a partial response.
However, the patient died of an infection shortly thereafter,
not thought to be related directly to the CTL infusions. The
other (Patient 11) had a CNS spindle cell tumour. The case
was originally discussed with the bank and it was decided
not to infuse cells in view of the lack of an evidence base for
the use of CTLs in this condition. The patient subsequently
developed typical PTLD. CTLs were infused with the PTLD
responding well, but the spindle cell tumour progressed and
the patient died.
Enquiries terminated by deaths of patients. Thirteen patients
died before any cells could be issued. It took an average of
6 d (range 2–11) between completion of the Initial Patient
Request Form and death. In ten cases, the patients died
before cells could be shipped. In three cases, the patient or
their families decided during the selection process that pallia-
tive care was preferable to active treatment and matched
CTLs were not shipped.
Enquiries resulting in a clinical decision not to issue CTLs. In
11 patients, the treating clinicians decided not to pursue
CTL therapy after the initial enquiry. Six did not have PTLD.
In three of these six cases it was decided there was no malig-
nancy present: in one of these cases infectious mononucleosis
was diagnosed. In two cases, there was an EBV-driven malig-
Table III. Enquiries resulting in issue of cells.
Patient
Age
(years) Sex
Reason for
immunosuppression Disease: site
HLA match/mismatch
(HLA-A,B,C,DR,DQ) Outcome
1 8 Female Mismatched cord blood
transplant for aplastic
anaemia
PTLD: nasopharynx,
lung, liver, CNS
1,1,1,1,1
0,0,0,0,0
Complete response
2 1 Female Congenital immune
deficiency
pre-cord blood
transplant
PTLD: CNS, lung,
kidney, liver,
lymph node
2,2,2,1,2
0,0,0,1,0
Complete response
3 14 Male VUD PBSCT for chronic
granulomatous disease
PTLD: lymph node 2,0,1,0,0
0,1,1,1,0
Progressive disease, died
4 53 Male Renal transplant PTLD: CNS 1,1,1,1,1
0,0,0,0,0
Complete response
5 1 Female Di George syndrome with
GVHD from maternal
cell graft
High EBV titres
pre-transplant
1,0,0,1,1
1,2,2,1,1
Not yet transplanted,
CTLs not yet infused
6 5 Male Cardiac transplant Leiomyosarcoma:
lung
Paternal donor Partial response, fatal
infection
7 55 Female VUD PBSCT for CML PTLD: CNS 1,1,1,1,1
1,1,0,1,1
Complete response
8 24 Female Cardiac transplant PTLD: lymph node 1,1,1,1,1
1,1,0,1,1
Complete response
9 4 Male VUD PBSCT for congenital
immune deficiency
PTLD: pulmonary,
liver
1,0,2,0,0
1,2,0,2,2
Progressive disease – died
10 1 Female Hepatic transplant PTLD: stomach,
duodenum
1,1,1,1,1
1,1,1,1,1
Complete response
11 13 Female Cardiac, renal transplants PTLD: lymph node.
EBV+ spindle cell:
CNS
2,1,1,2,2
0,1,1,0,0
Complete response for
PTLD, but spindle cell
tumour progressed.
12 56 Male VUD PBSCT for
aplastic anaemia
PTLD: lymph node 1,0,1,1,1
0,2,1,1,1
Complete response
Match/mismatch data are given at antigen level.
PTLD, post-transplant proliferative disorder; CNS, central nervous system; VUD, volunteer unrelated donor; PBSCT, peripheral blood stem cell
transplant; GVHD, graft-versus-host disease; CML, chronic myeloid leukaemia; EBV, Epstein-Barr virus; HLA, human leucocyte antigen; CTLs,
cytotoxic T lymphocytes.
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nant disorder (EBV+ diffuse large B cell lymphoma of the
elderly, haemophagocytic lymphohistiocytosis), but it was
decided by the referring clinicians not to proceed with infu-
sions. The other six cases of PTLD for whom infusions were
not pursued improved with conventional therapy after con-
tacting the cell bank.
HLA matching of patients with bank donors. After receipt of
the Initial Patient Enquiry form, the HLA types of CTLs and
patients at HLA-A, -B, -C, -DRB1 and -DQB1 were reviewed.
The maximum number of shared antigens was therefore 10.
No locus was preferentially matched. Where a patient had an
antibody specific to a CTL antigen, this CTL was not consid-
ered further in the allocation process. Where possible, allelic
level matching between CTLs and patients was assessed to
optimize CTL activity. Blood samples were requested to
monitor patients after each of the four weekly infusions and
12 weeks afterward. No CTL-directed HLA-specific antibod-
ies have been detected post-infusion in any of the patients.
To date, 36 HLA matching requests have been processed
and 32 allocation reviews completed. The minimum number
of antigens shared for both HLA class I and class II com-
bined was 2/10 and the maximum 9/10 (Fig 2). For the CTLs
infused, the minimum number of antigens shared was 3/10
and the maximum 9/10. Figure 2 understates the degree of
matching somewhat, as information was only available at
class I loci for two of the pairs (neither patient received infu-
sions). There was a median of three class I matches and two
class II matches. The degree of matching for class II
improved with time as the numbers within the bank built
up, but this effect was not apparent for class I. Those that
were issued had a slightly higher degree of matching (30 vs.
28 class I and 19 vs. 18 class II).
Results of matching for CTLs infused are given as number
of HLA-A, B, C, DR and DQB1 matches respectively
(Table III), so that, for example 1,0,2,1,0 indicates a single
matched allele/antigen at HLA-A and DR, two alleles/anti-
gens matched at HLA-C and none matched at HLA-B and
DQB1. For issue, we recommended at least one HLA class I
and one HLA class II match, based on our previous findings
that response rates correlated with number of matches and
CD4 cell counts, although it was the final decision of the
treating clinicians whether to proceed to infusion. Only 4/36
matches failed these criteria and all failed on having no HLA
class II match. Two of these (2,0,1,0,0 and 1,0,2,0,0) were
issued. It seems plausible that this poor HLA class II match-
ing contributed to these two patients (Patients 3, 9) being
the only ones with PTLD to show no clinical response.
Side effects. For ten of the 11 recipients, no side effects were
reported. One case (Patient 3) suffered from possible GVHD.
Five hours after the first infusion of anti-EBV CTLs, two
areas of petechiae were noted on the front and back of trunk.
The following day, the rash spread to c. 50% of the body
area. Although dissimilar to previous skin GVHD and not bi-
opsied, the most likely diagnosis was felt to be GVHD. Treat-
ment with topical steroid and tacrolimus resolved the rash
within 24 h. Subsequent infusions were not associated with
rashes, although the patient died shortly thereafter of refrac-
tory PTLD.
Discussion
We describe the establishment and operation of a GMP-com-
pliant, third-party, EBV-specific CTL bank manufactured
under all relevant EC regulation. By careful choice of the
HLA types of donors, a bank of only 25 donors was able to
supply cells to patients, with no request turned down solely
on the basis of poor HLA matching. In the first 2 years of its
operation, CTLs were issued to 12 patients and infused into
11. The outcomes of patients receiving cells for lymphopro-
liferative disease have been relatively good, with 8/10 achiev-
ing complete remission and only two dying of refractory
PTLD. However, neither patient receiving cells for EBV-asso-
ciated non-haematopoietic sarcoma responded well.
The main advantage of third party-derived cells compared
to autologous cells is relatively rapid availability after a diag-
nosis has been made. We set up the bank to issue cells
Fig 2. Human leucocyte antigen matching of
donors with recipients. The number of matches
at five human leucocyte antigen (HLA) loci are
shown as histograms of the best matched pro-
spective recipient–donor pairs. Matches that
resulted in cytotoxic T lymphocyte infusions
are shown in grey, those that did not in black.
For two pairs, information was only available
at HLA class I.
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within 14 d after initial contact. It is therefore disappointing
that 13 patients died within 11 d of contact. Most of the
patients about whom we were contacted were failing conven-
tional treatments at the time of request. Several potentially
avoidable delays were noted: in addition to the process of
cytotoxicity testing, it often took over a week to obtain
authorization for funding. In retrospect, it might have been
better if the bank had been contacted earlier in the courses
of these diseases. However, the median time to death was
16 d in a recent series of 40 patients with PTLD, with
around half of patients dying of their disease (Uhlin et al,
2014).
The favourable outcomes of the patients receiving cells for
PTLD and the high proportion of patients dying pre-licen-
sure support the view that CTLs comprise an effective treat-
ment modality. Third party donor-derived CTLs might be
expected to be less efficacious than fully HLA-matched CTLs,
but the outcomes from this bank, as well as other centres
(Doubrovina et al, 2012), have reported broadly similar out-
comes to the use of autologous cells. However, the patients
who died almost certainly had an intrinsically worse progno-
sis than those who received cells. It is also notable that six
patients with PTLD did not proceed to receiving infusions,
yet their disease improved in response to conventional treat-
ments. Overall, it seems likely that CTLs contributed to the
good outcomes of recipients. Nevertheless, the series we
report is descriptive and does not represent a formal test of
efficacy.
Of the four patients who received cells but died, there are
two notable features. First, two had a non-haematopoietic
sarcoma-like histology. Much less is known about the expres-
sion pattern of EBV genes in these tumours, which is likely
to differ from PTLD. Furthermore, the specificities of CTLs
directed against the LCLs used as antigenic stimulation
include non-EBV encoded, lymphoid-specific antigens (Long
et al, 2009), probably lacking in sarcomas. In addition, these
sarcomas are able to down-regulate expression of major his-
tocompatibility complex molecules (Berghuis et al, 2009).
These theoretical difficulties are borne out by our poor
results and alternative approaches for these patients are
needed. The two patients with PTLD who were refractory to
CTL infusions were notable for the lack of any HLA class II
matches and relatively aggressive clinical presentations. We
previously reported poor results from CTLs with low propor-
tions of CD4 cells (Haque et al, 2007), so these cases support
the view that CD4 cells are important for anti-PTLD efficacy.
It is, however, unclear whether the effects of CD4 cells are
due to directly mediated cytotoxicity or cytokine-mediated
help provided to CD8 cells. Doubrovina et al (2012) also
reported that clinically aggressive disease responded less well
to CTL infusions.
If the efficacy of EBV-specific CTLs is accepted, the ques-
tion arises as to which patients should be chosen for their
use. At present, two classes of patients seem particularly
appropriate and the recipients of our cells exemplify these
indications. First, PTLD resistant to conventional chemother-
apy, often CNS disease or CD20- and, consequently, resistant
to rituximab. The second class is situations where immuno-
suppression cannot be withdrawn, either because it is constit-
utive or where its reduction threatens graft, infection or
GVHD.
Indeed, given the lack of side effects compared to conven-
tional chemotherapeutic agents (Cruz et al, 2010) and their
apparent efficacy, third party anti-EBV CTLs may also be
indicated in other situations. Although rituximab can be
effective for PTLD, the short-term response rate is only
about 60–80% (Messahel et al, 2006; Burns et al, 2013; Cail-
lard et al, 2013; Styczynski et al, 2013) and the longer-term
prognosis may be worse (Heslop et al, 2010). Use of CTLs
might therefore be considered at an earlier stage in the thera-
peutic pathway. EBV is increasingly recognized as causing
lymphomas in situations other than post-transplant, includ-
ing secondary to other causes of immunosuppression, such
as HIV, drugs, such as methotrexate, or non-immunosup-
pressed individuals (Dojcinov et al, 2011; Ok et al, 2013).
The efficacy of CTLs remains to be tested in these contexts.
This report adds to the evidence that anti-EBV CTLs have
few side effects. However, one case of likely skin GVHD was
observed in the 2 d after one of the infusions. While we can-
not be sure that the CTLs were the cause of the rash, it is
notable that mild, transient skin GVHD has been reported
from other centres (Prockop et al, 2012; Leen et al, 2013).
No cases affecting other sites have been reported, although
GVHD of similarly mild severity affecting other organs may
well not be observable. It remains possible that a more severe
case of GVHD might occur in the future.
Overall, we report that a third party anti-EBV CTL bank
can be operated in accordance with GMP under current EU
legislation. Outcomes from patients receiving CTLs have
been good, especially if both HLA class I and II loci were
matched. However, a high proportion of patients died in the
period after the bank was alerted, but before any cells could
be issued. In the future, this CTL bank should be useful for
a wider range of patients within Europe.
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